284 related articles for article (PubMed ID: 2573424)
21. Increased erbB-2 gene copies and expression in multiple stages of breast cancer.
Iglehart JD; Kraus MH; Langton BC; Huper G; Kerns BJ; Marks JR
Cancer Res; 1990 Oct; 50(20):6701-7. PubMed ID: 2208136
[TBL] [Abstract][Full Text] [Related]
22. Detection of c-erbB-2 oncoprotein expression in breast tissue by multiparameter flow cytometry.
Li BD; Bauer KD; Carney WP; Duda RB
J Surg Res; 1993 Mar; 54(3):179-88. PubMed ID: 7682635
[TBL] [Abstract][Full Text] [Related]
23. Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population.
Descotes F; Pavy JJ; Adessi GL
Anticancer Res; 1993; 13(1):119-24. PubMed ID: 8097388
[TBL] [Abstract][Full Text] [Related]
24. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
[TBL] [Abstract][Full Text] [Related]
25. [Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of resected lung cancer].
Chiba W; Sawai S; Hanawa T; Ishida H; Matsui T; Kosaba S; Watanabe S; Hatakenaka R; Matsubara Y; Funatsu T
Gan To Kagaku Ryoho; 1993 Apr; 20(6):824-7. PubMed ID: 8098200
[TBL] [Abstract][Full Text] [Related]
26. [Amplification of c-myc and c-erbbeta-2(HER-2/neu) in breast cancer without axillary lymph node metastasis: correlation with other prognostic parameters].
Lizard-Nacol S; Arnould L; Riedinger JM; Arnal M; Collin F; Guerrin J
Bull Cancer; 1994 Sep; 81(9):780-4. PubMed ID: 7703567
[TBL] [Abstract][Full Text] [Related]
27. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.
Zhou D; Battifora H; Yokota J; Yamamoto T; Cline MJ
Cancer Res; 1987 Nov; 47(22):6123-5. PubMed ID: 3664511
[TBL] [Abstract][Full Text] [Related]
28. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer.
King CR; Swain SM; Porter L; Steinberg SM; Lippman ME; Gelmann EP
Cancer Res; 1989 Aug; 49(15):4185-91. PubMed ID: 2568168
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas.
Meyers SL; O'Brien MT; Smith T; Dudley JP
Cancer Res; 1990 Sep; 50(18):5911-8. PubMed ID: 1975511
[TBL] [Abstract][Full Text] [Related]
31. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas.
Park JB; Rhim JS; Park SC; Kimm SW; Kraus MH
Cancer Res; 1989 Dec; 49(23):6605-9. PubMed ID: 2573419
[TBL] [Abstract][Full Text] [Related]
32. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
33. Hormonal receptors, cell proliferation fraction (Ki-67) and c-erbB-2 amplification in breast cancer. Relationship between differentiation degree and axillary lymph node metastases.
Sirvent JJ; Santafé M; Salvadó MT; Alvaro T; Raventós A; Palacios J
Histol Histopathol; 1994 Jul; 9(3):563-70. PubMed ID: 7526910
[TBL] [Abstract][Full Text] [Related]
34. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
[TBL] [Abstract][Full Text] [Related]
35. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA
Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785
[TBL] [Abstract][Full Text] [Related]
36. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
37. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?
Tang RP; Kacinski B; Validire P; Beuvon F; Sastre X; Benoit P; dela Rochefordière A; Mosseri V; Pouillart P; Scholl S
J Cell Biochem; 1990 Nov; 44(3):189-98. PubMed ID: 1980125
[TBL] [Abstract][Full Text] [Related]
38. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification.
Courjal F; Theillet C
Cancer Res; 1997 Oct; 57(19):4368-77. PubMed ID: 9331100
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of the c-erbB-2 protein in human breast tumor cell lines.
Hynes NE; Gerber HA; Saurer S; Groner B
J Cell Biochem; 1989 Feb; 39(2):167-73. PubMed ID: 2565909
[TBL] [Abstract][Full Text] [Related]
40. Oncogene patterns in breast and ovarian carcinomas.
Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
